Use of molecular markers in samples obtained from preoperative aspiration of thyroid.

Several experiments have been carried out in order to find molecular markers that increase the diagnose accuracy of the Fine-Needle Aspiration (FNA), especially for thyroid lesions of undetermined significance. The growing number of published experiments on one or more of the different types of markers has started to justify the need to gather the pieces of information as a way to add evidence and guide the development of future research in the area. From the search arguments and criteria previously defined, 95 articles were selected from the electronic databases PUBMED, MEDLINE, SCOPUS and LILACS. From the 36 markers submitted to analysis and identified in preoperative FNA thyroid samples, only 10 (GAL3, CK-19, HBME-1, TPO, CD44, Telomerase, DAP IV, RAS, RET and BRAF) were assessed in more than two investigations, be it either in panel or individually. The minimum, medium and maximum values of sensibility, specificity, positive predictive value, negative predictive value and diagnose accuracy were obtained from the group of investigation, as well as the limitations and advantages of the use of each marker were identified. The BRAF mutation, for its unquestionable specificity, and the GAL3, for its regularity of average results obtained here, found in several locations in the cell as well as out of the cell, suggesting multiple functions of this molecule, were observed as holders of more expressive evidence in the effort of reducing the uncertainty of the diagnose in preoperative FNA of thyroid.

[1]  A. Bartolazzi,et al.  Methodology and Technical Requirements of the Galectin-3 Test for the Preoperative Characterization of Thyroid Nodules , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[2]  Yasuhiro Ito,et al.  Classification of thyroid follicular cell tumors: with special reference to borderline lesions. , 2012, Endocrine journal.

[3]  A. Nassar,et al.  HMGA2 Expression Analysis in Cytological and Paraffin-embedded Tissue Specimens of Thyroid Tumors by Relative Quantitative RT-PCR , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[4]  W. Kim,et al.  Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. , 2011, The Journal of clinical endocrinology and metabolism.

[5]  M. Henry,et al.  HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules , 2010, Cancer cytopathology.

[6]  C. Ki,et al.  BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. , 2010, The Journal of clinical endocrinology and metabolism.

[7]  D. Pacchioni,et al.  Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining , 2010, Virchows Archiv.

[8]  G. Fontanini,et al.  CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. , 2010, Thyroid : official journal of the American Thyroid Association.

[9]  Steven J. M. Jones,et al.  Diagnostic utility of galectin-3 in thyroid cancer. , 2010, The American journal of pathology.

[10]  M. Papotti,et al.  Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine‐needle aspirates suspicious for Hurthle cell neoplasms , 2009, Cancer.

[11]  J. Fletcher,et al.  Molecular Detection of PPARγ Rearrangements and Thyroid Carcinoma in Preoperative Fine-Needle Aspiration Biopsies , 2008, Endocrine pathology.

[12]  P. Dalla Palma,et al.  Expression of Cytokeratin 19 and Protein p63 in Fine Needle Aspiration Biopsy of Papillary Thyroid Carcinoma , 2008, Acta Cytologica.

[13]  M. P. Martegani,et al.  Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. , 2008, The Lancet. Oncology.

[14]  G. Troncone,et al.  Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings , 2007, Clinical endocrinology.

[15]  S. Mukhopadhyay,et al.  Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining , 2006, Modern Pathology.

[16]  B. Cho,et al.  Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto‐pathology diagnosis, especially in BRAFV600E mutation‐prevalent area , 2006, Clinical endocrinology.

[17]  D. Wilbur,et al.  The role of immunolocalization of CD57 and GLUT‐1 in cell blocks in fine‐needle aspiration diagnosis of papillary thyroid carcinoma , 2006, Cancer.

[18]  David D. Roberts,et al.  Proteomic Identification of New Biomarkers and Application in Thyroid Cytology , 2006, Acta Cytologica.

[19]  X. Qian,et al.  BRAF Mutation Analysis in Fine Needle Aspiration (FNA) Cytology of the Thyroid , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[20]  S. Suster Thyroid tumors with a follicular growth pattern: problems in differential diagnosis. , 2006, Archives of pathology & laboratory medicine.

[21]  J. Collet,et al.  Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples , 2005, British Journal of Cancer.

[22]  L. Mills,et al.  Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[23]  M. Papotti,et al.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. , 2005, Endocrine-related cancer.

[24]  M. Papotti,et al.  Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential , 2005, Modern Pathology.

[25]  A. Gasbarri,et al.  From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[26]  M. Miettinen,et al.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours , 1996, Virchows Archiv.

[27]  G. ClaudioLiberman,et al.  Detección de marcadores de malignidad en nódulos tiroideos por transcripción reversa y reacción en cadena de la polimerasa (RT-PCR) , 2003 .

[28]  A. Vecchione,et al.  Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas. , 2003, Anticancer research.

[29]  I. Goecke,et al.  [Detection of malignancy markers in thyroid nodules by reverse transcriptase polymerase chain reaction (RT-PCR)]. , 2003, Revista médica de Chile (Impresa).

[30]  T. Takano,et al.  Cancer-specific mRNAs in thyroid carcinomas: detection, use, and their implication in thyroid carcinogenesis. , 2002, Endocrine journal.

[31]  A Ippolito,et al.  Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. , 2001, Thyroid : official journal of the American Thyroid Association.

[32]  C. Cheung,et al.  Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.

[33]  F. de Nigris,et al.  FRA-1 expression in hyperplastic and neoplastic thyroid diseases. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  M. P. Martegani,et al.  Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Soares,et al.  Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287-294, 1998. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Z. Baloch,et al.  Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. , 1999, Human pathology.

[37]  A. Miyauchi,et al.  Accurate and objective preoperative diagnosis of thyroid papillary carcinomas by reverse transcription-PCR detection of oncofetal fibronectin messenger RNA in fine-needle aspiration biopsies. , 1998, Cancer research.

[38]  G. Botti,et al.  Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. , 1998, Cancer research.

[39]  A. Kovatich,et al.  Immunocytochemical evaluation of HBME‐1, CA 19‐9, and CD‐15 (Leu‐M1) in fine‐needle aspirates of thyroid nodules , 1998, Diagnostic cytopathology.

[40]  C. Kandaraki,et al.  Evaluation of HMFG2 and thyroglobulin in the diagnosis of thyroid fine needle aspiration (FNA) , 1997, Cytopathology : official journal of the British Society for Clinical Cytology.

[41]  P. Ladenson,et al.  Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. , 1996, Archives of internal medicine.

[42]  V. Alves,et al.  Lactoferrin in thyroid lesions: immunoreactivity in fine needle aspiration biopsy samples. , 1996, Acta cytologica.

[43]  M. Weiss,et al.  Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene , 1996, International journal of cancer.

[44]  M. Ostrowski,et al.  Leu‐7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms , 1995, Diagnostic cytopathology.